Miyagawa, Ippei
Nakayamada, Shingo
Tanaka, Yoshiya
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (N/A)
Ministry of Education, Culture, Sports, Science and Technology of Japan (N/A)
Japan Agency for Medical Research and Development (N/A)
University of Occupational and Environmental Health, Japan (N/A)
UOEH Grant for Advanced Research (N/A)
Article History
First Online: 20 March 2019
Compliance with Ethical Standards
:
: Y. Tanaka received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, AbbVie, Pfizer, YL Biologics, Bristol-Myers, Glaxo-SmithKline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, and Asahi-kasei, and research grants from Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, Taisho-Toyama. S. Nakayamada received speaking fees and/or honoraria from Bristol-Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Asahi-kasei and Pfizer (less than $10,000 each), and also research grants from Mitsubishi-Tanabe, Takeda, Novartis and MSD.
: This article does not contain any studies with human or animal subjects performed by any of the authors.